Endo Case Study

Endo Case Study - Jeffrey Witt Business Policy and Strategy...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Jeffrey Witt Business Policy and Strategy Endo Pharmaceuticals Case Study Group #6 Endo Pharmaceuticals Case Study If two businesses were to merge together the first step in considering to move forward would be to understand the company’s prior background information. “Algos was broad-based technology development company innovating a new class of drugs utilizing NMDA antagonists to block pain impulses. Since going public in 1995, Algos had brought several products to Phase II clinical trials. During that period, Algos added some partnerships with several pharmaceutical companies and accumulated a deficit of $49 million on minimal revenues. As Ammon considered the merger of the two businesses, she commented: “If the Algos technology works, you would have equivalent analgesia with half the narcotic. This technique could be combined with existing analgesics to produce a whole new class of drugs that could obsolete all of today’s pain management products.”” ( http://cb.hbsp.harvard.edu/cb/web/he/product_view.seam?
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 03/04/2011 for the course BUS 101 taught by Professor Surie during the Spring '11 term at Nassau CC.

Page1 / 2

Endo Case Study - Jeffrey Witt Business Policy and Strategy...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online